• MJHLS Brand Logo

© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.

Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars

May 02, 2024

Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.

FDA Approves High-Concentration Cyltezo

May 01, 2024

Biosimilars Policy Roundup: April 2024

May 01, 2024

Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability

April 30, 2024

Clinical Experience With Initiating Adalimumab Biosimilars

April 29, 2024

Featured Content

Switching From Adalimumab to a Biosimilar

April 29th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar.

FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi

April 29th 2024

By Skylar Jeremias

Article

The approval marks the sixth for a biosimilar referencing Herceptin (trastuzumab) for the treatment of HER2-positive breast and gastric cancers.

Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar

April 29th 2024

By Skylar Jeremias

Article

The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.

Adam Colborn Reviews Biosimilar Interchangeability Requirements, Advocates for Pharmacist Resources

April 28th 2024

By Cameron Santoro

Video

In an interview with Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy focuses on biosimilar interchangeability and approaches to encourage wider adoption in dispensing these medications.

The Totality of Evidence Supporting the Approval of Adalimumab Biosimilar GP2017

April 27th 2024

By Deana Ferreri, PhD

Article

A review article summarized the totality of evidence supporting the approval of the adalimumab biosimilar GP2017 (Hyrimoz; Sandoz) in the United States and Europe.

The Top 5 Biosimilar Articles for the Week of April 22

April 26th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 22, 2024.

Formycon Reports 83% Revenue Increase in 2023

April 25th 2024

By Skylar Jeremias

Article

Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a total of €77.7 million, according to its annual earnings report.

AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access

April 24th 2024

By Skylar Jeremias

Article

Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.

AON Saves Over $243 Million With High Biosimilar Adoption

April 22nd 2024

By Skylar Jeremias

Article

Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.

Sustainable Biosimilar Markets Achieve Widespread Market Uptake Through Collective Action

April 22nd 2024

By Cameron Santoro

Article

Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar market uptake by fostering collaboration for long-term benefits.